SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BigKNY3 who wrote (19975)3/22/1999 2:16:00 PM
From: Mkilloran  Read Replies (2) of 23519
 
BigKNY3....Wall Street Analyst will react to the improvements in VIVUS's roleout of MUSE in Europe. Expected increase in sales in the 2nd qtr. Progress on Alibra in Phase II trials, Gene Therapy report to be presented in May, potential for a female SD gel/cream,etc.

We will also confirm progress on a US partner, Japan, etc in the conf call.

As there is progress on these activities I expect we will see upgrades from some Wall Street analyst and additional coverage from other brokers as well.

There have been many improvements since last July that will benefit
Vivus shareholders. Many of whom have bought Vivus in the $2-3 price range.

As well as those that have lowered their adv cost of Vivus shares at these lower stock prices.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News